AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11692292 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (400 mg twice per day)
Number of subjects: 187
Study 11692292 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg twice per day)
Number of subjects: 187
Study 11692292 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 187
Study 11692292 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 187
Study 9134917 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate beverage
Number of subjects: 30
Study 9134917 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 30
Study 7950180 — intervention group
Group type: EXPERIMENTAL
Intervention: Jian Yan Ling (JYL)
Number of subjects: 128
Study 7950180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 3110804 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g L-carnitine daily for 3 weeks
Number of subjects: 40
Study 3110804 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g L-carnitine single oral dose
Number of subjects: 40
Study 3110804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29729237 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg nightly)
Number of subjects: 69
Study 29729237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 28760798 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastomeric infusion pump (Baxter Infusor)
Number of subjects: 0
Study 28760798 — intervention group
Group type: COMPARATOR
Intervention: Electronic infusion pump (ambIT Continuous)
Number of subjects: 0
Study 28760798 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pumps
Number of subjects: 0
Study 26277548 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (70 IU/kg body weight/day)
Number of subjects: 30
Study 26277548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22946487 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (750 mg) with MDMA (75 mg)
Number of subjects: 17
Study 22946487 — intervention group
Group type: COMPARATOR
Intervention: MDMA (75 mg)
Number of subjects: 17
Study 22946487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22946487 — intervention group
Group type: COMPARATOR
Intervention: Metyrapone (750 mg)
Number of subjects: 17
Study 21958886 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg clopidogrel loading dose
Number of subjects: 201
Study 21958886 — intervention group
Group type: COMPARATOR
Intervention: 300-mg clopidogrel loading dose
Number of subjects: 201
Study 18400718 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid eicosapentaenoic acid (EPA) capsules (1.5 g/d) for 6 months
Number of subjects: 52
Study 18400718 — intervention group
Group type: COMPARATOR
Intervention: No supplement (controls)
Number of subjects: 52
Study 17409863 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (100 mg/m for 3 of 4 weeks) and carboplatin (AUC = 6 mg/ml/min once every 4 weeks)
Number of subjects: 403
Study 17409863 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel or observation as maintenance therapy after four cycles of chemotherapy
Number of subjects: 403
Study 12725879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg dry powder
Number of subjects: 921
Study 12725879 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 921
Study 10776684 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud packs and sulfur baths in addition to daily exposure to sun ultraviolet rays and regular bathing at the Dead Sea (Group 1)
Number of subjects: 42
Study 10776684 — intervention group
Group type: COMPARATOR
Intervention: Daily exposure to sun ultraviolet rays and regular bathing at the Dead Sea (Group 2)
Number of subjects: 42
Study 8737630 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxerutins (2 x 500 mg daily)
Number of subjects: 133
Study 1568584 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg MK-329
Number of subjects: 6
Study 3158321 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel (DG) 125 micrograms/day for 3 weeks
Number of subjects: 30
Study 3158321 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LN) 125 micrograms/day for 3 weeks
Number of subjects: 30
Study 31822925 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of vaporized synthetic 5‐methoxy‐N,N‐dimethyltryptamine
Number of subjects: 11
Study 30352583 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity group
Number of subjects: 1298
Study 30352583 — intervention group
Group type: COMPARATOR
Intervention: Health education group
Number of subjects: 1298
Study 27094716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 84
Study 27094716 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 84
Study 24952865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C levels (measured in plasma within 24 hours of admission)
Number of subjects: 16279
Study 24952865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C or genotype‐adjusted cystatin C levels
Number of subjects: 16279
Study 24952865 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endpoint (CV death or MI)
Number of subjects: 16279
Study 22633251 — intervention group
Group type: EXPERIMENTAL
Intervention: SOM-A (original MOVE program)
Number of subjects: 44
Study 22633251 — intervention group
Group type: COMPARATOR
Intervention: SOM-B (self-guided MOVE curriculum)
Number of subjects: 44
Study 21189766 — intervention group
Group type: EXPERIMENTAL
Intervention: Prop‐based oral health and nutrition intervention program (8‐10 minute duration)
Number of subjects: 90
Study 21189766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 21189766 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (both intervention and control)
Number of subjects: 90
Study 18721121 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu-TENS
Number of subjects: 46
Study 18721121 — intervention group
Group type: COMPARATOR
Intervention: Placebo-TENS
Number of subjects: 46
Study 15955217 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin 2 mg after somatostatin 250 microg/h
Number of subjects: 24
Study 15955217 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin 250 microg/h
Number of subjects: 24
Study 15955217 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin plus Terlipressin
Number of subjects: 24
Study 15955217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15955217 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin alone
Number of subjects: 24
Study 15955217 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 24
Study 15955217 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 24
Study 12802125 — intervention group
Group type: EXPERIMENTAL
Intervention: Kabat‐Zinn's mindfulness‐based stress reduction program
Number of subjects: 0
Study 12802125 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10735579 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 0
Study 10735579 — intervention group
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin (RTX)
Number of subjects: 0
Study 8679357 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine 3 mg kg‐1
Number of subjects: 10
Study 8679357 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 2049321 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantle radiotherapy followed by six cycles of adjuvant MVPP (RT + MVPP)
Number of subjects: 115
Study 2049321 — intervention group
Group type: COMPARATOR
Intervention: Mantle radiotherapy alone (RT)
Number of subjects: 115
Study 2049321 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (RT + MVPP)
Number of subjects: 115
Study 2049321 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (RT + MVPP and RT)
Number of subjects: 115
Study 6344698 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane, 0.7% end‐tidal
Number of subjects: 24
Study 6344698 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane, 0.4% end‐tidal
Number of subjects: 24
Study 6344698 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovar, 0.1 ml/kg, intravenously
Number of subjects: 24
Study 6344698 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine, 0.5 mg/kg, intravenously
Number of subjects: 24
Study 30869980 — intervention group
Group type: COMPARATOR
Intervention: CMA (Contingency Management for Abstinence)
Number of subjects: 110
Study 30869980 — intervention group
Group type: EXPERIMENTAL
Intervention: CMS (Contingency Management for Shaping cessation)
Number of subjects: 110
Study 29759832 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing (MPP)
Number of subjects: 381
Study 29759832 — intervention group
Group type: COMPARATOR
Intervention: Bi-V pacing
Number of subjects: 381
Study 29759832 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing (MPP) - MPP-AS
Number of subjects: 381
Study 29759832 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing (MPP) - MPP-Other
Number of subjects: 381
Study 29759832 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall safety of CRT-D system
Number of subjects: 381
Study 26087570 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer/fluoride dentifrice (0.3% triclosan, 2.0% copolymer, 1,450 ppm F)
Number of subjects: 135
Study 26087570 — intervention group
Group type: COMPARATOR
Intervention: Herbal/bicarbonate dentifrice (herbal extract, 1,400 ppm F)
Number of subjects: 135
Study 26087570 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrice (450 ppm F, 1,000 ppm F as sodium monofluorophosphate)
Number of subjects: 135
Study 23358446 — intervention group
Group type: EXPERIMENTAL
Intervention: Early percutaneous coronary intervention (E-PCI)
Number of subjects: 224
Study 23358446 — intervention group
Group type: COMPARATOR
Intervention: Selective PCI (S-PCI)
Number of subjects: 224
Study 23358446 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 224
Study 21339418 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational workbook
Number of subjects: 75
Study 21339418 — intervention group
Group type: COMPARATOR
Intervention: Usual care with a nephrologist
Number of subjects: 75
Study 19155896 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate (250 mg, weekly intramuscular injections starting at 16-20 weeks until delivery or 35 weeks)
Number of subjects: 134
Study 19155896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching injections, same schedule as intervention)
Number of subjects: 134
Study 17573388 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham pressure
Number of subjects: 40
Study 17573388 — intervention group
Group type: COMPARATOR
Intervention: Cricoid pressure (for laryngeal tube)
Number of subjects: 40
Study 17573388 — intervention group
Group type: COMPARATOR
Intervention: Cricoid pressure (for laryngeal tube-suction II)
Number of subjects: 40
Study 14767244 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained subjects (60%GET)
Number of subjects: 15
Study 14767244 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained subjects (80%GET)
Number of subjects: 15
Study 14767244 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained subjects (50%Delta)
Number of subjects: 15
Study 14767244 — intervention group
Group type: EXPERIMENTAL
Intervention: Untrained subjects (60%GET)
Number of subjects: 15
Study 14767244 — intervention group
Group type: EXPERIMENTAL
Intervention: Untrained subjects (80%GET)
Number of subjects: 15
Study 14767244 — intervention group
Group type: EXPERIMENTAL
Intervention: Untrained subjects (50%Delta)
Number of subjects: 15
Study 15567936 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent docetaxel (T)
Number of subjects: 326
Study 15567936 — intervention group
Group type: COMPARATOR
Intervention: Single-agent doxorubicin (A)
Number of subjects: 326
Study 10394163 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 107
Study 10394163 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 107
Study 10394163 — intervention group
Group type: COMPARATOR
Intervention: Control Group (noncardiac patients under GA)
Number of subjects: 107
Study 10394163 — intervention group
Group type: COMPARATOR
Intervention: Control Group (cardiac patients under GA)
Number of subjects: 107
Study 7747861 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 40
Study 7747861 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 40
Study 2202445 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured behavioural change programme
Number of subjects: 311
Study 2202445 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple advice programme
Number of subjects: 311
Study 2202445 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 311
Study 6788275 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl infusion
Number of subjects: 34
Study 6788275 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 30797266 — intervention group
Group type: EXPERIMENTAL
Intervention: ATT with cholecalciferol (Group-B)
Number of subjects: 496
Study 30797266 — intervention group
Group type: COMPARATOR
Intervention: ATT (Group-A)
Number of subjects: 496
Study 28852819 — intervention group
Group type: COMPARATOR
Intervention: −20° < AHP < 0° group
Number of subjects: 54
Study 28852819 — intervention group
Group type: EXPERIMENTAL
Intervention: 20° > AHP > 0° group
Number of subjects: 54
Study 28852819 — intervention group
Group type: EXPERIMENTAL
Intervention: 40° > AHP > 20° group
Number of subjects: 54
Study 28852819 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 54
Study 27072947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation group (experimental intervention)
Number of subjects: 60
Study 27072947 — intervention group
Group type: COMPARATOR
Intervention: Sham meditation group (active control)
Number of subjects: 60
Study 24412801 — intervention group
Group type: COMPARATOR
Intervention: 50 mg DKP
Number of subjects: 93
Study 24412801 — intervention group
Group type: COMPARATOR
Intervention: 25 mg DKP
Number of subjects: 93
Study 22333955 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification-based treatment approach
Number of subjects: 156
Study 22333955 — intervention group
Group type: COMPARATOR
Intervention: Usual physical therapy care
Number of subjects: 156
Study 18702848 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol
Number of subjects: 53
Study 18702848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich fraction (TRF)
Number of subjects: 53
Study 18702848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 17071953 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedimune Baby
Number of subjects: 6
Study 17071953 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedimune Junior
Number of subjects: 6
Study 17071953 — intervention group
Group type: COMPARATOR
Intervention: Branded drugs
Number of subjects: 6
Study 14687051 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (25 mcg, hospital-prepared capsule)
Number of subjects: 681
Study 14687051 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 681
Study 14687051 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone (1 mg gel)
Number of subjects: 681
Study 14687051 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone
Number of subjects: 681
Study 12117483 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% of maximum inspiratory pressure (P(imax))
Number of subjects: 16
Study 12117483 — intervention group
Group type: COMPARATOR
Intervention: Less than 5% of maximum inspiratory pressure (P(imax))
Number of subjects: 16
Study 10723516 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine-based multiple agent combinations (including protease inhibitor-containing and -sparing regimens, triple nucleoside RTI regimens, and regimens including non-nucleoside RTIs and/or hydroxyurea)
Number of subjects: 0
Study 10723516 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine-based multiple agent combinations
Number of subjects: 0
Study 7712309 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (5 MU three times per week for 6 months)
Number of subjects: 31
Study 7712309 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (5 MU daily for 6 months)
Number of subjects: 31
Study 7712309 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (5 MU three times per week or daily for 6 months)
Number of subjects: 31
Study 31843266 — intervention group
Group type: EXPERIMENTAL
Intervention: SIIPL-PCV
Number of subjects: 346
Study 31843266 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 346
Study 31178940 — intervention group
Group type: EXPERIMENTAL
Intervention: High medication necessity belief
Number of subjects: 292
Study 31178940 — intervention group
Group type: EXPERIMENTAL
Intervention: High concern belief about potential adverse effects
Number of subjects: 292
Study 31178940 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative belief toward medications
Number of subjects: 292
Study 31178940 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity
Number of subjects: 292
Study 31178940 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure encounter within the last 3 months
Number of subjects: 292
Study 31178940 — intervention group
Group type: EXPERIMENTAL
Intervention: Low medication necessity belief
Number of subjects: 292
Study 31178940 — intervention group
Group type: EXPERIMENTAL
Intervention: High medication concern belief
Number of subjects: 292
Study 31178940 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative medication belief
Number of subjects: 292
Study 31178940 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherence to medications
Number of subjects: 292
Study 28728854 — intervention group
Group type: EXPERIMENTAL
Intervention: BI-RADS Mammography Atlas 5th Edition for reporting and assessing lesions on DBCT
Number of subjects: 4
Study 26565077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine ER 10 mg BID
Number of subjects: 153
Study 26565077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine ER 5 mg BID
Number of subjects: 153
Study 26565077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 23563245 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1.7 g DHA and 0.6 g EPA)
Number of subjects: 174
Study 23563245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 20431530 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based antihypertensive treatment
Number of subjects: 7489
Study 20431530 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based antihypertensive treatment
Number of subjects: 7489
Study 20431530 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline quartiles of SUA
Number of subjects: 7489
Study 20431530 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-varying SUA
Number of subjects: 7489
Study 17956497 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg sulphadoxine/2.5 mg pyrimethamine
Number of subjects: 180
Study 17956497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 15757762 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and transarticular Kirschner wire fixation
Number of subjects: 19
Study 15757762 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (one or two lag screws or cerclage wire)
Number of subjects: 19
Study 12192104 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0
Study 12192104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9973898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral phlebography
Number of subjects: 1827
Study 7754939 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril treatment initiated < 24 hours after AMI
Number of subjects: 428
Study 7754939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study 2279540 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐2b interferon at 3 MU/day over 3 months and then 3 MU/three times/week over 9 months
Number of subjects: 107
Study 2279540 — intervention group
Group type: COMPARATOR
Intervention: no further treatment (control group)
Number of subjects: 107
Study 2279540 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐2b interferon
Number of subjects: 107
Study 6793924 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylate of lysine (1.8 g)
Number of subjects: 40
Study 6793924 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylate of lysine (3.6 g)
Number of subjects: 40
Study 6793924 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine (30 mg)
Number of subjects: 40
Study 6793924 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine (60 mg)
Number of subjects: 40
Study 30347587 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipedicular approach
Number of subjects: 382
Study 30347587 — intervention group
Group type: COMPARATOR
Intervention: Bipedicular approach
Number of subjects: 382
Study 27841694 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice rehabilitation post-radiotherapy
Number of subjects: 65
Study 27841694 — intervention group
Group type: COMPARATOR
Intervention: Control group (no voice rehabilitation)
Number of subjects: 65
Study 26303134 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 μg BID for 8 weeks
Number of subjects: 15
Study 23525738 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sevoflurane (1.5 MAC)
Number of subjects: 120
Study 23525738 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose sevoflurane (1.0 MAC)
Number of subjects: 120
Study 23525738 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sevoflurane (0.5 MAC)
Number of subjects: 120
Study 23525738 — intervention group
Group type: COMPARATOR
Intervention: No sevoflurane (control)
Number of subjects: 120